

13 Jul 2021

Bristol-Myers Squibb International Corporation

Email: Clinical.Trials@bms.com

Chaussée de la Hulpe 185

Brussels, Belgium

1170

EudraCT Number: 2015-001924-40

Sponsor Protocol Number: GED-0301-CD-003

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of adult and adolescent subjects with active Crohn's disease

Trial 2015-001924-40 was withdrawn with 0 patients enrolled. As such no results are reported.